Free tool
Drugs in development
Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations
Drugs in development
3,685
Not FDA-approved
In Phase 3
1,424
Highest phase reached
Matching your filters
18
18 drugs in development
Names, sponsors and conditions come from the trial records. Click a drug for its trials.
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- AmrubicinJapan onlyPhase 34 trials
Gilead Sciences · Small Cell Lung Cancer, Extensive Stage Small Cell Lung Cancer (ES-SCLC), Small Cell Lung Cancer (SCLC)
- DazodalibepVIB 4920, MEDI 4920Phase 33 trials
Amgen · Sjögren's Syndrome (SS), Sjögren's Syndrome, Sjogren's Syndrome
- OlpasiranAMG 890Phase 33 trials
Amgen · Cardiovascular Disease, Atherosclerotic Cardiovascular Disease
- RocatinlimabAMG 451Phase 33 trials
Amgen · Atopic Dermatitis
- ABP 206Phase 32 trials
Amgen · Melanoma
- ABP 234Phase 32 trials
Amgen · Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC), Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
- BisphosphonatePhase 32 trials
Ultragenyx Pharmaceutical Inc · Osteogenesis Imperfecta
- XaluritamigAMG 509Phase 32 trials
Amgen · Metastatic Castration-resistant Prostate Cancer
- ABP 692Phase 31 trial
Amgen · Relapsing-remitting Multiple Sclerosis (RRMS)
- ABP 938Phase 31 trial
Amgen · Neovascular Age-related Macular Degeneration, nAMD
- BemarituzumabPhase 31 trial
Amgen · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- EU-authorized NivolumabPhase 31 trial
Amgen · Melanoma
- FDA-licensed NivolumabPhase 31 trial
Amgen · Melanoma
- AnvumetostatAMG 193Phase 23 trials
Amgen · Advanced MTAP-null Solid Tumors, MTAP-deleted NSCLC, MTAP-null Non-Small-Cell Lung Cancer
- AMG 732Phase 22 trials
Amgen · Thyroid Eye Disease
- DaxdilimabHZN-7734Phase 21 trial
Amgen · Idiopathic Inflammatory Myositis
- IDE397Phase 21 trial
Amgen · MTAP-null Non-Small-Cell Lung Cancer, MTAP-null Solid Tumors
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.